Increased serum tumor markers (CA125 and CA15.3) in primary plasma cell leukemia: A case report and review of the literature

Clinical Lymphoma and Myeloma

Volumn 8, Issue 5, 2008, Pages 312-314

  De Larrea, Carlos Fernández ^a   Cibeira, Maria Teresa ^a   Vallansot, Rolando ^a   Colomo, Lluís ^b   Bladé, Joan ^b  

^a Institute of Hematology and Oncology

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Bone pain; Cyclophosphamide; Liver infiltration; Mucin; Multiple myeloma

Indexed keywords

ALPHA FETOPROTEIN; CA 125 ANTIGEN; CA 15-3 ANTIGEN; CA 19-9 ANTIGEN; CD56 ANTIGEN; CYCLOPHOSPHAMIDE; CYTOKERATIN 19 FRAGMENT; DEXAMETHASONE; ENOLASE; FRESH FROZEN PLASMA; HEMOGLOBIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN LIGHT CHAIN; SYNDECAN 1; TUMOR MARKER; ZOLEDRONIC ACID; MUCIN 1;

AGED; ANTIGEN EXPRESSION; ARTICLE; BONE PAIN; CANCER SCREENING; CASE REPORT; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; DEATH; ECHOGRAPHY; FEMALE; FEMUR; FEVER; HEMOGLOBIN BLOOD LEVEL; HEMOPERITONEUM; HUMAN; HYPERCALCEMIA; IMMUNOGLOBULIN BLOOD LEVEL; KIDNEY DISEASE; LIVER BIOPSY; LIVER DISEASE; LIVER METASTASIS; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; OSTEOLYSIS; PALLOR; PLASMA CELL; PLASMA CELL LEUKEMIA; REST; SEPTIC SHOCK; SOLID TUMOR; STAPHYLOCOCCUS INFECTION; TREATMENT RESPONSE; URINARY EXCRETION; WEIGHT REDUCTION; ANEMIA; BLOOD; FATALITY; LIVER; PAIN; PATHOLOGY; PATHOPHYSIOLOGY;

AGED; ANEMIA; CA-125 ANTIGEN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; FATAL OUTCOME; FEMALE; HUMANS; LEUKEMIA, PLASMA CELL; LIVER; MUCIN-1; PAIN; SHOCK, SEPTIC; TUMOR MARKERS, BIOLOGICAL; WEIGHT LOSS;

EID: 58149347647     PISSN: 15579190     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2008.n.045     Document Type: Article

References (19)

1. Bladé J, Kyle RA. Nonsecretory myeloma, immunoglobulin D myeloma, and plasma cell leukaemia. Hematol Oncol Clin North Am 1999; 13:1259-72.
2. Noel P, Kyle RA. Plasma cell leukaemia: an evaluation of response to therapy. Am J Med 1987; 83:1062-8.
3. Garcia-Sanz R, Orfao A, Gonzalez M, et al. Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy and cytogenetic characteristics. Blood 1999; 93:1032-7.
4. Saccaro S, Fonseca R, Veillon DM, et al. Primary plasma cell leukemia: report of 17 new cases treated with autologous or allogeneic stem-cell transplantation and review of the literature. Am J Hematol 2005; 78:288-94.
5. Avet-Loiseau H, Daviet A, Brigaudeau C, et al. Cytogenetic, interphase and multicolor fluorescence in situ hybridization analysis in primary plasma cell leukemia: a study of 40 patients at diagnosis, on behalf of the Intergroupe Francophone du Myelome and the Groupe Francais de Cytogenetique Hematologique. Blood 2001; 97:822-5.
6. Hayman SR, Fonseca R. Plasma cell leukemia. Curr Treat Options Oncol 2001; 2:205-16.
7. Iwasaki T, Hamano T, Aizawa K, et al. Increased serum CA125 levels in plasma cell dyscrasias. Acta Haematol 1997; 98:104-8.
8. Luminari S, Goldaniga M, Ceccherelli F, et al. Prevalence and prognostic significance of sMUC-1 levels in plasma cell dyscrasias. Br J Haematol 2003; 121:772-4.
9. Takahashi T, Makigushi Y, Hinoda Y, et al. Expression of MUC1 on myeloma cells and induction of HLA-unrestricted CTL against MUC1 from a multiple myeloma patient. J Immunol 1994; 153:2102-9.
10. Hayes DF, Sekine H, Ohno T, et al. Use of a murine monoclonal antibody for detection of circulating plasma DF3 antigen levels in breast cancer patients. J Clin Invest 1985; 75:1671-8.
11. Vizcarra E, Lluch A, Cibrián R, et al. Value of CA 15.3 in breast cancer and comparison with CEA and TPA: a study of specificity in diseasefree follow-up patients and sensitivity in patients at diagnosis of the first metastasis. Breast Cancer Res Treat 1996; 37:209-16.
12. Al Saati T, Caveriviere P, Gorguet B, et al. Epithelial membrane antigen in hematopoietic neoplasms. Hum Pathol 1986; 17:533-4.
13. Treon SP, Maimonis P, Bua D, et al. Elevated soluble MUC1 levels and decreased anti-MUC1 antibody levels in patients with multiple myeloma. Blood 2000; 96:3147-53.
14. Canney PA, Moore M, Wilkinson, PM, et al. Ovarian cancer antigen CA125: a prospective clinical assessment of its role as tumour marker. Br J Cancer 1984; 50:765-9.
15. Wei G, Yuping Z, Jun W, et al. CA125 expression in patients with non- Hodgkin's lymphoma. Leuk Lymphoma 2006; 47:1322-6.
16. Bairey O, Blickstein D, Stark P, et al. Serum CA 125 as a prognostic factor in non-Hodgkin's lymphoma. Leuk Lymphoma 2003; 44:1733-8.
17. Batlle M, Ribera JM, Oriol A, et al. Usefulness of tumor markers CA 125 and CA 15.3 at diagnosis and during follow-up in non-Hodgkin's lymphoma: study of 200 patients. Leuk Lymphoma 2005; 46:1471-6.
18. Lazzarino M, Orlandi E, Catherine K, et al. Serum CA 125 is of clinical value in the staging and follow-up of patients with non-Hodgkin's lymphoma: correlation with tumor parameters and disease activity. Cancer 1998; 82:576-82.
19. Dilek I, Ayakte H, Demir C, et al. CA125 levels in patients with non- Hodgkin lymphoma and other hematologic malignancies. Clin Lab Haematol 2005; 27:51-5.